Importantly, uptake of 89Zr-GT-00AxIL15 in the tumor was significantly higher compared to the untargeted 89Zr-MOPCxIL15 construct at both doses (high dose 5.4% vs. 1.9%, low dose 4.4% vs. 1.9%) (Figure 5B), confirming that TA-MUC1 binding improves tumor accumulation. This evidence concerns the gene MUC1 and neoplasm.